Nanocarriers for effective delivery of benznidazole and nifurtimox in the treatment of chagas disease: A review.

Autor: Arrúa EC; Área Técnica Farmacéutica, Departamento de Farmacia, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas Argentina, Argentina., Seremeta KP; Consejo Nacional de Investigaciones Científicas y Técnicas Argentina, Argentina; Departamento de Ciencias Básicas y Aplicadas, Universidad Nacional del Chaco Austral, Cte. Fernández 755, 3700, Pcia. Roque Sáenz Peña, Chaco, Argentina., Bedogni GR; Consejo Nacional de Investigaciones Científicas y Técnicas Argentina, Argentina., Okulik NB; Consejo Nacional de Investigaciones Científicas y Técnicas Argentina, Argentina; Departamento de Ciencias Básicas y Aplicadas, Universidad Nacional del Chaco Austral, Cte. Fernández 755, 3700, Pcia. Roque Sáenz Peña, Chaco, Argentina., Salomon CJ; Área Técnica Farmacéutica, Departamento de Farmacia, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas Argentina, Argentina. Electronic address: csalomon@fbioyf.unr.edu.ar.
Jazyk: angličtina
Zdroj: Acta tropica [Acta Trop] 2019 Oct; Vol. 198, pp. 105080. Date of Electronic Publication: 2019 Jul 09.
DOI: 10.1016/j.actatropica.2019.105080
Abstrakt: Neglected tropical diseases (NTDs) constitute a group of infectious diseases prevalent in countries with tropical and subtropical climate that affect the poorest individuals and produce high chronic disability associated with serious problems for the health system and socioeconomic development. Chagas disease or American trypanosomiasis is included on the NTDs list. However, even though this disease affects more than 10 million people, mostly in Latin America, causing the death of over 10,000 people every year, only two drugs are approved for its treatment, benznidazole and nifurtimox. These antiparasitic agents were developed almost half a century ago and present several biopharmaceutical disadvantages such as low aqueous solubility and permeability limiting their bioavailability. In addition, both therapeutic agents are available only as tablets and a liquid pediatric formulation is still lacking. Therefore, novel pharmaceutical strategies to optimize the pharmacotherapy of Chagas disease are urgently required. In this regard, nanotechnological approaches may be a crucial alternative for the delivery of both drugs ensuring an effective pharmacotherapy although the successful bench-to-bedside translation remains a major challenge. The present work reviews in detail the formulation and in-vitro/in-vivo analysis of different nanoformulations of nifurtimox and benznidazole in order to enhance their solubility, dissolution, bioavailability and trypanocidal activity.
(Copyright © 2019 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: